ArticleIranian journal of pharmaceutical research : IJPR
Anticancer Effects of
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objectives: The current study aimed to use an integrated approach involving network pharmacology, in-silico molecular docking and dynamics simulations, as well as in-vitro experimental validation, to study the anticancer effects of Methods: A total of 133 phytochemicals from Results: Five phytochemicals (Spiradine A, Jujubogenin, Malkangunin, Ceanothic Acid, Moupinamide) showed no toxicity risks. The compound-target network identified 305 targets, with 160 intersecting BC targets. The PPI network (160 nodes, 568 edges, P < 1.0e-16) revealed EGFR, HSP90AA1, and STAT3 as hubs. GO/KEGG analyses linked targets to cancer pathways. EGFR, HSP90AA1, and STAT3 showed higher expression in tumors (P < 0.05), with EGFR/STAT3 linked to poorer survival (P < 0.05). Jujubogenin docking yielded binding affinities of -8.7 (EGFR), -7.5 (HSP90AA1), and -8.2 kcal/mol (STAT3). MD simulations confirmed stable EGFR/STAT3 complexes. The extract exhibited selective cytotoxicity, reduced colony formation, induced apoptosis (P < 0.05), and downregulated EGFR (70%), HSP90AA1 (60%), and STAT3 (90%) at 100 µg/mL (P < 0.01). Conclusions: Network pharmacology revealed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.